
Elysium Health Stock
Scientific health products
Sign up today and learn more about Elysium Health Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Elysium Health Stock
Elysium Health’s mission is to solve the challenges in health with science, to help people live healthier and longer. Elysium works directly with scientists, clinicians and health professionals worldwide the world to translate advances in science and technology into innovative health products that work. Our product development pipeline begins with research and development, continues with preclinical studies, and culminates with human clinical trials to demonstrate the safety and efficacy of products. Throughout this process, Elysium’s focus is to develop compounds found in nature that allow people to support their health proactively. Elysium is guided by a Scientific Advisory Board, which includes multiple winners of the Nobel Prize, as well as researchers and doctors who are experts in chemistry, physiology, neuroscience, complex chemical systems, biochemistry, and many other fields of study. Basis, Elysium Health’s first product, is a proprietary formulation of two ingredients designed to support long-term health at the cellular level. Basis is clinically proven to increase NAD+ levels, which decline with age. NAD+ is required for energy creation, regulating circadian rhythms, maintaining healthy DNA, and hundreds of other biological functions. Learn more via our science journal Endpoints: https://endpoints.elysiumhealth.com
Investors
Breyer Capital
Oscar Health, Circle, Shield AI, Stash Financial, Prosper Marketplace, C3 IoT, Grammarly, Etsy, Cleerly, Mark43
General Catalyst Partners
Snap, Jet, Stripe, Anduril Industries, Devoted Health, Lacework, Relativity Space, Oscar Health, Circle, Hopin
Morningside Group
OS Fund
Pivot Bio, Emulate, Tempo Automation, Human Longevity, Verge Genomics, Elysium Health, uBiome, 3T Biosciences
Silicon Valley Bank
One97, Olive, FireEye, Weee!, Workrise, Fair, project44, Plume Design, BetterUp, Welltok
Sound Ventures
Bird, ConsenSys, Noom, Chainalysis, SentinelOne, Capsule, Fundbox, MoonPay, Cedar, Mark43
Funding History
October 2015 | $1.1M |
---|---|
October 2015 | $6.2M |
October 2016 | $22.0M |
Management
CEO & Co-Founder
Eric Marcotulli
COO & Co-Founder
Dan Alminana
Chief Scientist & Co-Founder
Leonard Guarente
Chief Design Officer
Andrew Lin
Press
Forbes - Mar, 21 2019
Opportunities For Biotech Companies May Exist In The Anti-Aging MarketForbes - Feb, 13 2019
The Challenges In Bringing An Anti-Aging Pill To Marketbusinesswire - Jan, 24 2019
The Good Housekeeping Institute Partners with Elysium HealthTM to Launch ‘GH Wellness Lab’ at Hearst Towerlaw - Jan, 23 2019
ChromaDex Prepared to Proceed with Patent Infringement Action Against Elysium Healthalivenewspaper - Nov, 6 2018
Recap of 2018 for Elysium Healthweeklyopinion - Nov, 1 2018
The Supplement Basis by Elysium Healthchronicleweek - Oct, 18 2018
Elysium Health: a Supplement Company on a Missiongazetteday - Oct, 10 2018
Elysium Health Announces Its Cellular Health Product Basis is NSF Certified for Sportpositivethefacts - Sep, 22 2018
Answering Common Questions about Basis by Elysium HealthForbes - Aug, 2 2018
The Future of Aging: Bringing Hollywood to the HospitalEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase